Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (2021)
Attributed to:
BRIC: Packaging cell lines for inherently manufacturable viral vectors
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.21.00917
PubMed Identifier: 34464155
Publication URI: http://europepmc.org/abstract/MED/34464155
Type: Journal Article/Review
Volume: 39
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 30
ISSN: 0732-183X